Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2Cl.Mg |
Molecular Weight | 95.211 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg++].[Cl-].[Cl-]
InChI
InChIKey=TWRXJAOTZQYOKJ-UHFFFAOYSA-L
InChI=1S/2ClH.Mg/h2*1H;/q;;+2/p-2
DescriptionSources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium
phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.
CNS Activity
Sources: DOI: 10.1002/0471238961.0218151310010311.a02Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQChttps://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of manganese, calcium, magnesium and lithium on the ouabain-induced seizure. | 1977 |
|
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors. | 1977 Apr |
|
[Magnesium--an alternative in treatment resistant tachyarrhythmias]. | 1977 May 30 |
|
Characterization of the prolactin receptor in human prostate. | 1983 Nov |
|
Symptomatic hypercalcaemia precipitated by magnesium therapy. | 1985 Jan |
|
Regulation of membrane histamine H1-receptor binding sites by guanine nucleotides, mono- and divalent cations. | 1986 Apr |
|
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes. | 1986 Sep |
|
Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. | 1987 Mar 30 |
|
Effect of magnesium diet in gentamicin-induced acute renal failure in rats. | 1989 |
|
Polylysine specifically activates the insulin-dependent insulin receptor protein kinase. | 1989 Jun 15 |
|
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain. | 1990 Feb 5 |
|
Role of magnesium in cardiac tachyarrhythmias. | 1990 Jun 19 |
|
Modulation of mu, delta and kappa opioid receptors in rat brain by metal ions and histidine. | 1990 May |
|
Magnesium inhibits the hypertensive but not the cardiotonic actions of low-dose epinephrine. | 1991 Jun |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Overexpressed protein kinase C-delta and -epsilon subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake. | 1994 Feb 18 |
|
Cocaine-induced cerebrovasospasm and its possible mechanism of action. | 1994 Mar |
|
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid. | 1995 Mar |
|
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. | 1996 Jun |
|
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. | 2004 May |
|
In vitro application of endotoxin to thoracic aortas from magnesium-deficient rats enhances vascular hyporeactivity to phenylephrine. | 2004 Oct |
|
Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. | 2005 Oct |
|
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. | 2005 Oct |
|
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain. | 2006 Apr 25 |
|
Structure of pyrimidine 5'-nucleotidase type 1. Insight into mechanism of action and inhibition during lead poisoning. | 2006 Jul 21 |
|
Activation and enzymatic characterization of recombinant human kallikrein 8. | 2006 Jun |
|
Evidence for a two-step mechanism involved in the formation of covalent HC x TSG-6 complexes. | 2006 Jun 20 |
|
Kinetic properties of chimeric class I aldehyde dehydrogenases for retinal isomers. | 2006 Oct |
|
Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. | 2007 Nov |
|
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007 Sep |
|
Interactions between magnesium and psychotropic drugs. | 2008 Jun |
|
Cocaine use disorders and serum magnesium profile. | 2009 |
|
Differential binding of inorganic particles to MARCO. | 2009 Jan |
|
The loop connecting metal-binding domains 3 and 4 of ATP7B is a target of a kinase-mediated phosphorylation. | 2009 Jun 23 |
|
Magnesium modifies fentanyl-induced local antinociception and hyperalgesia. | 2009 Nov |
|
Evidence that TRPM7 is required for breast cancer cell proliferation. | 2009 Sep |
|
Hair tissue mineral analysis and metabolic syndrome. | 2009 Sep |
|
Involvement of transient receptor potential melastatin-related 7 (TRPM7) channels in cadmium uptake and cytotoxicity in MC3T3-E1 osteoblasts. | 2010 Dec 15 |
|
Carcinogenic heavy metals replace Ca2+ for DNA binding and annealing activities of mono-ubiquitinated annexin A1 homodimer. | 2010 Oct 1 |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. II. Binding affinity and conformational changes. | 2011 Feb |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition. | 2011 Feb |
|
Mechanically enforced bond dissociation reports synergistic influence of Mn2+ and Mg2+ on the interaction between integrin α7β1 and invasin. | 2011 Jul-Aug |
|
NADH fluorescence lifetime analysis of the effect of magnesium ions on ALDH2. | 2011 May 30 |
|
Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis. | 2013 |
|
Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum. | 2013 Apr |
|
Ofloxacin induces apoptosis via β1 integrin-EGFR-Rac1-Nox2 pathway in microencapsulated chondrocytes. | 2013 Feb 15 |
|
Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1. | 2013 Feb 25 |
|
Catalytic contribution of threonine 244 in human ALDH2. | 2013 Feb 25 |
|
Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis. | 2013 Jun 15 |
|
Assessment of infantile mineral imbalances in autism spectrum disorders (ASDs). | 2013 Nov 11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27995243
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm
were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29730
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
657
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
529832
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
232-094-6
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
7786-30-3
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
100000090109
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
59XN63C8VM
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
1311539
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | RxNorm | ||
|
59XN63C8VM
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
DTXSID5034690
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
SUB14421MIG
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
24584
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
6636
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | |||
|
m6996
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76656
Created by
admin on Fri Dec 15 15:46:35 GMT 2023 , Edited by admin on Fri Dec 15 15:46:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD